296 related articles for article (PubMed ID: 30018258)
81. TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.
Bronder D; Tighe A; Wangsa D; Zong D; Meyer TJ; Wardenaar R; Minshall P; Hirsch D; Heselmeyer-Haddad K; Nelson L; Spierings D; McGrail JC; Cam M; Nussenzweig A; Foijer F; Ried T; Taylor SS
Dis Model Mech; 2021 Nov; 14(11):. PubMed ID: 34569598
[TBL] [Abstract][Full Text] [Related]
82. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
Tuna M; Ju Z; Yoshihara K; Amos CI; Tanyi JL; Mills GB
Br J Cancer; 2020 Feb; 122(3):405-412. PubMed ID: 31780779
[TBL] [Abstract][Full Text] [Related]
83. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
84. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
85. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
86. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
87. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
[TBL] [Abstract][Full Text] [Related]
88. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
[TBL] [Abstract][Full Text] [Related]
89. The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
De Paolis E; Pietragalla A; De Bonis M; Fagotti A; Urbani A; Scambia G; Minucci A
Mol Biol Rep; 2021 Mar; 48(3):2985-2992. PubMed ID: 33656647
[TBL] [Abstract][Full Text] [Related]
90. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
[TBL] [Abstract][Full Text] [Related]
91. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
[TBL] [Abstract][Full Text] [Related]
92. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Szabova L; Bupp S; Kamal M; Householder DB; Hernandez L; Schlomer JJ; Baran ML; Yi M; Stephens RM; Annunziata CM; Martin PL; Van Dyke TA; Weaver Ohler Z; Difilippantonio S
PLoS One; 2014; 9(4):e95649. PubMed ID: 24748377
[TBL] [Abstract][Full Text] [Related]
93. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
94. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract][Full Text] [Related]
95. Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma.
Kutilin DS; Tsandekova MR; Porkhanova NV
Bull Exp Biol Med; 2021 Jan; 170(3):332-339. PubMed ID: 33452985
[TBL] [Abstract][Full Text] [Related]
96. HMGA2 and high-grade serous ovarian carcinoma.
Wu J; Wei JJ
J Mol Med (Berl); 2013 Oct; 91(10):1155-65. PubMed ID: 23686260
[TBL] [Abstract][Full Text] [Related]
97. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
98. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
99. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
100. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
